The Challenge of Cryptogenic Stroke and Silent Atrial Fibrillation
Cryptogenic stroke (CS) remains a diagnostic enigma and a therapeutic challenge in contemporary neurology, representing approximately one-third of all ischemic stroke admissions. While the clinical presentation is often indistinguishable from other embolic events, the absence of a clear etiology—such as large-vessel atherosclerosis, small-vessel disease, or a known cardioembolic source—complicates long-term management. Silent paroxysmal atrial fibrillation (PAF) is widely suspected to be the occult culprit in a significant proportion of these cases. However, the transient and asymptomatic nature of PAF makes it notoriously difficult to capture using conventional monitoring techniques like 24-hour or 48-hour Holter monitoring.
Existing guidelines have historically been ambiguous regarding the timing and selection criteria for long-term continuous ECG monitoring. While the CRYSTAL AF trial previously demonstrated the superiority of internal loop recorders (ILR) over standard care at six months, questions remain about the efficacy of ultra-early monitoring and whether specific cardiac biomarkers or imaging findings can help identify high-risk patients who would benefit most from such invasive diagnostics. The CRIPTOFAST Randomized Controlled Trial was designed to address these gaps, evaluating the efficacy of ultra-early ILR implantation and the predictive value of subtle left atrial (LA) anomalies.
